The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer
Open Access
- 5 July 2022
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 194 (3) , 577-586
Abstract
Purpose: The need for sentinel lymph node biopsy (SLNB) in clinically node-negative (cN0) patients is currently questioned. Our objective was to investigate the cost-effectiveness of a preoperative noninvasive lymph node staging (NILS) model (an artificial neural network model) for predicting pathological nodal status in patients with cN0 breast cancer (BC). Methods: A health-economic decision-analytic model was developed to evaluate the utility of the NILS model in reducing the proportion of cN0 patients with low predicted risk undergoing SLNB. The model used information from a national registry and published studies, and three sensitivity/specificity scenarios of the NILS model were evaluated. Subgroup analysis explored the outcomes of breast-conserving surgery (BCS) or mastectomy. The results are presented as cost (€) and quality-adjusted life years (QALYs) per 1000 patients. Results: All three scenarios of the NILS model reduced total costs (–€93,244 to –€398,941 per 1000 patients). The overall health benefit allowing for the impact of SLNB complications was a net health gain (7.0–26.9 QALYs per 1000 patients). Sensitivity analyses disregarding reduced quality of life from lymphedema showed a small loss in total health benefits (0.4–4.0 QALYs per 1000 patients) because of the reduction in total life years (0.6–6.5 life years per 1000 patients) after reduced adjuvant treatment. Subgroup analyses showed greater cost reductions and QALY gains in patients undergoing BCS. Conclusion: Implementing the NILS model to identify patients with low risk for nodal metastases was associated with substantial cost reductions and likely overall health gains, especially in patients undergoing BCS.Keywords
Funding Information
- Region Skåne
- Erling-Perssons Stiftelse
- Vetenskapsrådet (2020-01491)
- Medicinska Fakulteten, Lunds Universitet
- the governmental Funding of Clinical Research within the National Health Service (ALF young researcher Ida Skarping)
- Lund University
This publication has 32 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomesJournal of Cancer Survivorship, 2012
- Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: entinel node vs bservation after axillary ltraSou )The Breast, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast CancerJNCI: Journal of the National Cancer Institute, 2011
- A prospective cohort study defining utilities using time trade‐offs and the Euroqol‐5D to assess the impact of cancer‐related lymphedemaCancer, 2010
- Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical reviewInternational Journal of Technology Assessment in Health Care, 2008
- Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trialThe Lancet Oncology, 2007
- Multicentre validation study of sentinel node biopsy for staging in breast cancerBritish Journal of Surgery, 2005
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990